Cancer Medicines Forum: kick-off meeting
Table of contents
This first meeting of EMA's Cancer Medicines Forum looked at challenges around research into optimising cancer treatments. These included dose-optimisation and similar approaches tailored to the characteristics of the patient and the disease.
The CMF aims to explore how EMA can contribute towards addressing remaining uncertainties about the use of cancer medicines in clinical practice.
The forum brings together representatives of academic organisations from EMA’s Healthcare Professionals Working Party and the European medicines regulatory network.
The results of discussions will support the prioritisation of actions to fight cancer in EMA's Regulatory Science Strategy to 2025 and Academia Collaboration Matrix Action Plan.
The meetings of the forum are by invitation only.
EMA launched the CMF together with the European Organisation for Research and Treatment of Cancer (EORTC) in March 2022.
EMA will review the composition and procedures of the forum after a one-year pilot phase.
-
List item
Launch of EMA’s Cancer Medicines Forum with Academia (PDF/500.12 KB)
First published: 31/03/2022 -
List item
Minutes of the Cancer Medicines Forum - 31st March 2022 (PDF/138.02 KB)
First published: 27/07/2022
Last updated: 24/03/2023 -
List item
Presentation - Trial to optimize immunotherapy in early TNBC (M. Ignatiadis, Institut Bordet, Université Libre de Bruxelles) (PDF/103.06 KB)
First published: 24/03/2023 -
List item
Presentation - Case study on TNBC optimisation trial (Institut Bordet) (PDF/159.39 KB)
First published: 24/03/2023